J. Safra Sarasin Holding AG Buys 106,109 Shares of Boston Scientific Corporation $BSX

J. Safra Sarasin Holding AG increased its stake in Boston Scientific Corporation (NYSE:BSX) by 52.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 306,758 shares of the medical equipment provider’s stock after buying an additional 106,109 shares during the period. J. Safra Sarasin Holding AG’s holdings in Boston Scientific were worth $29,949,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Riverwater Partners LLC raised its position in shares of Boston Scientific by 3.3% in the 2nd quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock worth $333,000 after acquiring an additional 98 shares in the last quarter. Gerber Kawasaki Wealth & Investment Management grew its stake in Boston Scientific by 3.8% in the second quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock worth $291,000 after purchasing an additional 99 shares during the period. Crown Wealth Group LLC raised its holdings in Boston Scientific by 4.7% in the third quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock worth $218,000 after purchasing an additional 100 shares in the last quarter. IVC Wealth Advisors LLC lifted its position in Boston Scientific by 4.9% during the second quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock valued at $236,000 after buying an additional 102 shares during the period. Finally, Sound View Wealth Advisors Group LLC boosted its holdings in shares of Boston Scientific by 3.9% during the 2nd quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider’s stock valued at $294,000 after buying an additional 103 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Insider Activity

In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. This represents a 42.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 80,204 shares of company stock valued at $7,998,563 in the last quarter. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Performance

BSX stock opened at $93.66 on Tuesday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50. The company has a market cap of $138.85 billion, a P/E ratio of 50.09, a price-to-earnings-growth ratio of 1.68 and a beta of 0.67. The stock’s fifty day moving average price is $95.54 and its 200-day moving average price is $99.76.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. UBS Group reissued a “buy” rating on shares of Boston Scientific in a research report on Wednesday, December 17th. Needham & Company LLC reiterated a “buy” rating on shares of Boston Scientific in a report on Thursday, January 15th. Leerink Partners upped their price target on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. Barclays raised their price objective on Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Finally, Royal Bank Of Canada increased their target price on Boston Scientific from $125.00 to $130.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $123.89.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.